Young researchers: Eloïse Giabicani

Eloïse Giabicani

MD, PhD University Lecturer – Hospital Practitioner

Endocrine Functional Explorations
Reference Center for Rare Endocrine Diseases of Growth and Development – CRESCENDO
Molecular Endocrinology and Imprinting Pathologies UF – Hôpital Armand Trousseau

Center de Recherche Saint-Antoine – IGF system and fetal and postnatal growth – Sorbonne University / Inserm

Awards / Distinctions

• 2023 “Young investigator” award European Society of Pediatric endocrinology (ESPE), The Hague

Training

Dr. Eloïse Giabicani holds a Diplôme d’Études Spécialisées (DES) in Pediatrics and a Diplôme Inter-Universitaire (DIU) in Pediatric Endocrinology and Diabetology. She also completed a Master 2 in Endocrinology and Metabolism. Her university thesis focused on the pathophysiological contribution of diseases subject to parental imprinting to our understanding of growth and the IGF system.

After initial training in pediatrics, Dr. Giabicani chose to combine basic research and clinical practice by specializing in endocrinology, with a particular interest in fetal growth restriction and its consequences. Her main motivation lies in taking a translational approach to the care of patients with rare growth anomalies.

In this way, its clinical and fundamental research, aimed at gaining a better understanding of these pathologies, finds a direct application for the patients concerned, giving them their full meaning. Our aim is to help improve treatment and care for these patients, by linking scientific discoveries to clinical practice.

Research project

The most recent work focuses on the development of cellular models of rare epigenetic pathologies of fetal growth.

Eloïse Giabicani’s team’s approach is based on induced pluripotent stem cells, but also on stem cells derived from dental pulp, which are differentiated into cell types involved in the patient’s phenotype.

The idea, by understanding the underlying pathophysiological mechanisms at play in these diseases, is then to be able to improve the management of these patients but also better anticipate the consequences for individuals born with fetal growth restriction, who represent around 7% of births in France. These individuals are exposed to an increased risk of metabolic complications in adulthood, which are now well described but still poorly understood.

Publications

• Imprinting Disorders. Eggermann T, Monk D, Perez de Nanclares G, Kagami M, Giabicani ERiccio A, Tümer Z, Kalish J, Tauber M, Duis J, Weksberg R, Maher E, Begemann M, Elbracht M. Nature Reviews Disease Primers 2023 Jun 29;9(1):33.
• Maintenance of methylation profile in imprinting control regions in human induced pluripotent stem cells. Pham A, Selenou C, Giabicani E, Fontaine V, Marteau S, Brioude F, David L, Mitanchez D, Sobrier ML, Netchine I. Clin Epigenetics. 2022 Dec 28;14(1):190.
• Dental pulp stem cells as a promising model to study imprinting diseases. Giabicani EPham A, Selenou C, Sobrier ML, Andrique C, Lesieur J, Linglart A, Poliard A, Chaussain C, Netchine I. International Journal of Oral Science, 2022 Apr;14(19).
• Height and body mass index in molecularly-confirmed Silver-Russell syndrome and the long-term effects of growth hormone treatment. Sodipe OK, Giabicani ECanton APM, Ferrand N, Child J, Wakeling EL, Binder G, Netchine I, Mackay DJG, Inskip HM, Byrne CD, Temple IK, Davies, JH. Clinical Endocrinology (Oxf), 2022 Mar 9.
• Transcriptional profiling at the DLK1/MEG3 domain explains clinical overlap between imprinting disorders. Abi Habib W, Brioude F, Azzi S, Rossignol S, Linglart A, Sobrier ML, Giabicani EHarbison MD, Le Bouc Y and Netchine I. Science advances. 2019 feb; 5: eaau9425 22.
• Increasing knowledge in IGF1R defects in fetal growth retardation: lessons from 35 new patients. Giabicani EWillems M, Steunou V, Chantot-Bastaraud S, Thibaud N, Abi Habib W, et al. Journal of Medical Genetics. 2020 Mar;57(3):160-168.
• Roles of Type 1 Insulin-Like Growth Factor (IGF) Receptor and IGF-II in Growth Regulation: Evidence From a Patient Carrying Both an 11p Paternal Duplication and 15q Deletion. Giabicani EChantot-Bastaraud S, Bonnard A, Rachid M, Whalen S, Netchine I, et al. Frontiers in Endocrinology. 2019;10:263.
• Chromosome 14q32.2 imprinted region disruption as an alternative molecular diagnosis of Silver-Russell Syndrome. Geoffron S, Abi Habib W, Chantot-Bastaraud S, Dubern B, Steunou V, Canton A, Busa T, Dufourg MN, Esteva B, Fradrin M, Geneviève D, Isidor B, Linglart A, Oliver Petit I, Phillip, Picard, Pienkowski C, Rio M, Rossignol S, Sandreau C,Tauber M, Thevenon J, Vu-Hong TA, Harbison MH, Brioude F, Netchine I, Giabicani E. Journal of Clinical Endocrinology and Metabolism. 2018 Jul 1;103(7):2436-2446.
• Diagnosis and management of Silver-Russell syndrome: first international consensus statement. Wakeling EL, Brioude F, Lokulo-Sodipe O, O’Connell SM, Salem J, Bliek J, Canton AP, Chrzanowska KH, Davies JH, Dias RP, Dubern B, Elbracht M, Giabicani EGrimberg A, Grønskov K, Hokken-Koelega AC, Jorge AA, Kagami M, Linglart A, Maghnie M, Mohnike K, Monk D, Moore GE, Murray PG, Ogata T, Petit IO, Russo S, Said E, Toumba M, Tümer Z, Binder G, Eggermann T, Harbison MD, Temple IK, Mackay DJ, Netchine I. Nature Reviews Endocrinology. 2017 Feb;13(2):105-124.